View Author
patient genotype treatment study therapy hepatitis myeloma factor university steatosi stage hepatitis c ribavirin signi thalidomide outcome group liver baseline virus concentration infection cancer table level survival treatment outcome response progression plasma hospital score signi ficantly hcv rna risk factors dexamethasone trial interferon guci score ishak serum cirrhosis hepatitis c virus department 50 years high-dose therapy -10 protein incidence disease figure blood analysis high-dose fibrosis prophylaxi hcv genotype 1 brosi 24 weeks lenalidomide thrombosis body mass index phase chemotherapy venou hcv-rna hematology venous thromboembolism il 28b randomized value fi brosis genotype 1 warfarin index result ficant combination erasmus mc risk factor
10 Most Recent Publications
|
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis c genotype 2 or 3
(Article)
Alsiö, A.̊. Rembeck, K. Nasic, S. Westin, J. Hellstrand, K. Norkrans, G. Lagging, M. Askarieh, G. Christensen, P.B. Färkkilä, M. Langeland, N. Buhl, M.R. Pedersen, C. Mørch, K. Haagmans, B.L. |
2012-05-24
|
|
Response prediction in chronic hepatitis c by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
(Article)
Lagging, M. Askarieh, G. Neumann, A.U. Pawlotsky, J.M. Haagmans, B.L. Zeuzem, S. Bochud, P.-Y. Hellstrand, K. Negro, F. Bibert, S. Söderholm, J. Westin, J. Lindh, M. Romero, A. Missale, G. Ferrari, C. |
2011-03-04
|
|
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(Article)
Kyle, R. Durie, B.G.M. San Miguel, J-F. Avet-Loiseau, H. Hajek, R. Chen, W. Anderson, K.C. Ludwig, H. Sonneveld, P. Pavlovsky, S. Palumbo, A. Richardson, P.G. Rajkumar, S.V. Barlogie, B. Greipp, P. Vescio, R. Turesson, I. Westin, J. Boccadoro, M. Landgren, O. Bladé, J. Merlini, G. Kröger, N. Einsele, H. Vesole, D. Dimopoulos, M.A. |
2010-04-22
|
|
Nonresponder patients with hepatitis C virus genotype 2/3 infection: A question of low systemic interferon concentrations?
(Article)
Alsiö, A.̊. Christensen, P.B. Norkrans, G. Lagging, M. Färkkilä, M. Langeland, N. Buhl, M.R. Pedersen, C. Mørch, K. Haagmans, B.L. Westin, J. Hellstrand, K. |
2010-02-15
|
|
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10 549 patients from the International Myeloma Working Group
(Article)
Ludwig, H. Durie, B.G.M. Westin, J. Harousseau, J-L. Beksac, M. Boccadoro, M. Palumbo, A. Barlogie, B. Shustik, C. Cavo, M. Greipp, P. Joshua, D. Bolejack, V. Attal, M. Sonneveld, P. Crowley, J. Turesson, I. Kyle, R. Bladé, J. Fonseca, R. Dimopoulos, M.A. Shimizu, K. Miguel, J.S. |
2008-04-15
|
|
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
(Article)
Palumbo, A. Rajkumar, S.V. Attal, M. Belch, A. Knop, S. Joshua, D. Sezer, O. Ludwig, H. Vesole, D. Bladé, J. Kyle, R. Westin, J. Dimopoulos, M.A. Weber, D. Bringhen, S. Niesvizky, R. Waage, A. Lilienfeld-Toal, M. Von Lonial, S. Morgan, G. Orlowski, R.Z. Shimizu, K. Anderson, K.C. Richardson, P.G. Boccadoro, M. Durie, B.G.M. Sonneveld, P. Hussein, M. San Miguel, J-F. Barlogie, B. Harousseau, J-L. Zonder, J.A. Cavo, M. Zangari, M. |
2008-02-01
|
|
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
(Article)
Westin, J. Ydreborg, M. Hellstrand, K. Lagging, M. Islam, S. Alsiö, A.̊. Dhillon, A.P. Pawlotsky, J.M. Zeuzem, S. Schalm, S.W. Ferrari, C. Neumann, A.U. |
2008-01-07
|
|
Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C [5]
(Article)
Westin, J. Hellstrand, K. Lagging, M. Alsiö, A.̊. Ydreborg, M. Ferrari, C. Neumann, A.U. Pawlotsky, J.M. Schalm, S.W. Zeuzem, S. Verhey-Hart, E. |
2007-05-01
|
|
Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]
(Article)
Lukasiewicz, E. Hellstrand, K. Verhey-Hart, E. Lagging, M. Westin, J. Ferrari, C. Neumann, A.U. Pawlotsky, J.M. Schalm, S.W. Zeuzem, S. Veldt, B.J. Hansen, B.E. |
2007-01-01
|
|
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection
(Article)
Westin, J. Lagging, M. Missale, G. Neumann, A.U. Hellstrand, K. Dhillon, A.P. Norkrans, G. Romero, A.I. Pawlotsky, J.M. Zeuzem, S. Schalm, S.W. Verheij-Hart, E. Negro, F. |
2007-01-01
|
